Expert Opinion on Pharmacotherapy

Papers
(The H4-Index of Expert Opinion on Pharmacotherapy is 19. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)
ArticleCitations
Perspectives on the advances in the pharmacotherapeutic management of Duchenne muscular dystrophy36
Comprehensive overview of the available pharmacotherapy for the treatment of non-neurogenic overactive bladder in children36
Pharmacotherapy developments in autophagy inhibitors for bladder cancer36
Real-world safety and effectiveness of roxadustat in patients with anemia of chronic kidney disease: interim results from a post-marketing surveillance study in Japan34
Rheumatoid arthritis in Latin America: pharmacotherapy and clinical challenges33
Evaluating the safety and efficacy of seladelpar for adults with primary biliary cholangitis30
Efficacy of 3-day versus 5-day aprepitant regimens for long-delayed chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based chemotherapy29
Promising therapies for adults with symptomatic obstructive hypertrophic cardiomyopathy: 2023 and beyond28
Chemotherapy in resectable or potentially resectable colon cancer with liver metastases28
Advances in the management of obstructive hypertrophic cardiomyopathy: The role of mavacamten24
Current treatment options for Mycobacterium marinum cutaneous infections22
Antidepressant medications in women aged 40 and older and the risk of fragility fractures: a systematic literature review and meta-analysis22
GnRH agonists and antagonists in therapy of symptomatic uterine fibroids – current roles and future perspectives21
An overview of mineralocorticoid receptor antagonists as a treatment option for patients with heart failure: the current state-of-the-art and future outlook21
The pharmacological treatment and management of hyperhidrosis20
A 2023 update on the advancements in the treatment of agitation in Alzheimer’s disease20
Momelotinib in myelofibrosis20
How useful is chemotherapy for atypical and anaplastic meningiomas?20
Selecting optimal therapy in systemic mastocytosis: current state and future directions19
0.087157964706421